<DOC>
	<DOCNO>NCT00811356</DOCNO>
	<brief_summary>The purpose study determine study drug ( antimalarial medication ) safe give healthy subject single dose repeated dos , understand effect food single dos study drug determine study drug effect approve medication rosiglitazone rosuvastatin .</brief_summary>
	<brief_title>A First Time Human Study Healthy Volunteers Investigate New Medicine Treat Malaria</brief_title>
	<detailed_description>Malaria type parasitic infection , common tropical subtropical region world , include part Americas , Asia , Africa . In recent year rapid spread drug resistant malaria make necessary develop new antimalarial treatment . In animal study , GSK932121 show able kill malaria parasite fully active drug resistant malaria parasite . It hop information collect study lead improve treatment malaria . This first time human fusion study 3 part : Part A - single dose escalation/ food effect : study study drug give only- first low dose group participant dose increase previous dose find safe . It also look effect food study drug body Part B - repeat dose escalation : study study drug give daily 7 day - first low dose group participant dose increased next group previous dose find safe Part B - drug-drug interaction : study study drug give daily 7 day dose determine safe previous group participant look effect study drug specific approve medication ( rosiglitazone -- diabetic medication rosuvastatin -- cholesterol lower medication ) body . Safety assess measurement vital sign , cardiac monitoring , spirometry , collection adverse event assessment , renal biomarkers laboratory safety test .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male female 18 50 year age , inclusive Females nonchildbearing potential ( premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea Body weight &gt; 50 kg BMI within range 19 31 kg/m2 ( inclusive ) QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block Positive prestudy drug/alcohol screen Positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody History regular alcohol consumption within 6 month study Participation clinical trial investigational product within 30 day 5 halflives investigational product ( whichever longer ) prior start new study Exposure four new drug within 12 month prior first dose day Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication History sensitivity study medication , component thereof history drug allergy would contraindicate Donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . History sensitivity heparin history heparininduced thrombocytopenia heparin use maintain patency intravenous cannula . Asthma history asthma Smoking history regular use tobacco nicotinecontaining product within 2 month prior screen Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Food Effect</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Antimalarial</keyword>
	<keyword>First Time In Human</keyword>
	<keyword>Single Dose</keyword>
	<keyword>Repeat Dose</keyword>
</DOC>